TY - JOUR
T1 - Persistent morbidity in Clade IIb mpox patients: interim results of a long-term follow-up study, Belgium, June to November 2022
AU - ITM Monkeypox Study Group
AU - Berens-Riha, Nicole
AU - Bracke, Stefanie
AU - Rutgers, Jojanneke
AU - Burm, Christophe
AU - Van Gestel, Liesbeth
AU - Hens, Matilde
AU - Kenyon, Chris
AU - Bottieau, Emmanuel
AU - Soentjens, Patrick
AU - Brosius, Isabel
AU - Van Esbroeck, Marjan
AU - Vercauteren, Koen
AU - van Griensven, Johan
AU - van Dijck, Christophe
AU - Liesenborghs, Laurens
N1 - FTX; DOAJ (CC BY 4.0)
PY - 2023
Y1 - 2023
N2 - While mpox was well characterised during the 2022 global Clade IIb outbreak, little is known about persistent morbidity. We present interim results of a prospective cohort study of 95 mpox patients assessed 3-20 weeks post-symptom onset. Two-thirds of participants had residual morbidity, including 25 with persistent anorectal and 18 with genital symptoms. Loss of physical fitness, new-onset/worsened fatigue and mental health problems were reported in 36, 19 and 11 patients, respectively. These findings require attention by healthcare providers.
AB - While mpox was well characterised during the 2022 global Clade IIb outbreak, little is known about persistent morbidity. We present interim results of a prospective cohort study of 95 mpox patients assessed 3-20 weeks post-symptom onset. Two-thirds of participants had residual morbidity, including 25 with persistent anorectal and 18 with genital symptoms. Loss of physical fitness, new-onset/worsened fatigue and mental health problems were reported in 36, 19 and 11 patients, respectively. These findings require attention by healthcare providers.
U2 - 10.2807/1560-7917.ES.2023.28.7.2300072
DO - 10.2807/1560-7917.ES.2023.28.7.2300072
M3 - A1: Web of Science-article
C2 - 36795501
VL - 28
JO - Eurosurveillance
JF - Eurosurveillance
SN - 1560-7917
IS - 7
ER -